Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 45

1.

High-Dose Rituximab and Early Remission in PLA2R1-Related Membranous Nephropathy.

Seitz-Polski B, Dahan K, Debiec H, Rousseau A, Andreani M, Zaghrini C, Ticchioni M, Rosenthal A, Benzaken S, Bernard G, Lambeau G, Ronco P, Esnault VLM.

Clin J Am Soc Nephrol. 2019 Aug 7;14(8):1173-1182. doi: 10.2215/CJN.11791018. Epub 2019 Jul 24.

PMID:
31340979
2.

Rituximab bioavailability in primary membranous nephropathy.

Boyer-Suavet S, Andreani M, Cremoni M, Brglez V, Benzaken S, Bernard G, Nachman P, Esnault V, Seitz-Polski B.

Nephrol Dial Transplant. 2019 Mar 30. pii: gfz041. doi: 10.1093/ndt/gfz041. [Epub ahead of print] No abstract available.

PMID:
30929012
3.

Only Follow-Up of Memory B Cells Helps Monitor Rituximab Administration to Patients with Neuromyelitis Optica Spectrum Disorders.

Lebrun C, Cohen M, Rosenthal-Allieri MA, Bresch S, Benzaken S, Marignier R, Seitz-Polski B, Ticchioni M.

Neurol Ther. 2018 Dec;7(2):373-383. doi: 10.1007/s40120-018-0101-4. Epub 2018 Jun 7.

4.

Interleukin 6 and high-sensitivity C-reactive protein are potential predictive markers of response to infliximab in hidradenitis suppurativa.

Montaudié H, Seitz-Polski B, Cornille A, Benzaken S, Lacour JP, Passeron T.

J Am Acad Dermatol. 2017 Jan;76(1):156-158. doi: 10.1016/j.jaad.2016.08.036. No abstract available.

PMID:
27986139
5.

Interleukin 17 alone is not a discriminant biomarker in early demyelinating spectrum disorders.

Lebrun C, Cohen M, Pignolet B, Seitz-Polski B, Bucciarelli F, Benzaken S, Kantarci O, Siva A, Okuda D, Pelletier D, Brassat D; on behalf SFSEP, BIONAT Network; RISC.

J Neurol Sci. 2016 Sep 15;368:334-6. doi: 10.1016/j.jns.2016.07.052. Epub 2016 Jul 25.

PMID:
27538659
6.

Epitope Spreading of Autoantibody Response to PLA2R Associates with Poor Prognosis in Membranous Nephropathy.

Seitz-Polski B, Dolla G, Payré C, Girard CA, Polidori J, Zorzi K, Birgy-Barelli E, Jullien P, Courivaud C, Krummel T, Benzaken S, Bernard G, Burtey S, Mariat C, Esnault VL, Lambeau G.

J Am Soc Nephrol. 2016 May;27(5):1517-33. doi: 10.1681/ASN.2014111061. Epub 2015 Nov 13.

7.

Cross-reactivity of anti-PLA2R1 autoantibodies to rabbit and mouse PLA2R1 antigens and development of two novel ELISAs with different diagnostic performances in idiopathic membranous nephropathy.

Seitz-Polski B, Dolla G, Payré C, Tomas NM, Lochouarn M, Jeammet L, Mariat C, Krummel T, Burtey S, Courivaud C, Schlumberger W, Zorzi K, Benzaken S, Bernard G, Esnault VL, Lambeau G.

Biochimie. 2015 Nov;118:104-15. doi: 10.1016/j.biochi.2015.08.007. Epub 2015 Aug 19.

PMID:
26296473
8.

Prediction of membranous nephropathy recurrence after transplantation by monitoring of anti-PLA2R1 (M-type phospholipase A2 receptor) autoantibodies: a case series of 15 patients.

Seitz-Polski B, Payré C, Ambrosetti D, Albano L, Cassuto-Viguier E, Berguignat M, Jeribi A, Thouret MC, Bernard G, Benzaken S, Lambeau G, Esnault VL.

Nephrol Dial Transplant. 2014 Dec;29(12):2334-42. doi: 10.1093/ndt/gfu252. Epub 2014 Jul 25.

PMID:
25063424
9.

[Coordination of health vigilances: for a global management of hospital risks].

Quaranta JF, Canivet N, Darmon MJ, Jambou P, Rocher F, Staccini P, Benzaken S, Paquis P.

Transfus Clin Biol. 2008 Nov;15(5):284-8. doi: 10.1016/j.tracli.2008.09.012. Epub 2008 Oct 18. Review. French.

PMID:
18930680
10.

Glucose intolerance and hypoadiponectinemia are already present in lean patients with chronic hepatitis C infected with genotype non-3 viruses.

Anty R, Gelsi E, Giudicelli J, Mariné-Barjoan E, Gual P, Benzaken S, Saint-Paul MC, Sadoul JL, Huet PM, Tran A.

Eur J Gastroenterol Hepatol. 2007 Aug;19(8):671-7.

PMID:
17625437
11.

Serum C-reactive protein: a non-invasive marker of alcoholic hepatitis.

Vanbiervliet G, Le Breton F, Rosenthal-Allieri MA, Gelsi E, Marine-Barjoan E, Anty R, Piche T, Benzaken S, Saint-Paul MC, Huet PM, Tran A.

Scand J Gastroenterol. 2006 Dec;41(12):1473-9.

PMID:
17101579
12.

Infliximab and human immunodeficiency virus infection: Viral load reduction and CD4+ T-cell loss related to apoptosis.

Filippi J, Roger PM, Schneider SM, Durant J, Breittmayer JP, Benzaken S, Bernard A, Dellamonica P, Hébuterne X; Groupe d'Etude Niçois Polyvalent en Infectiologie (GENPI).

Arch Intern Med. 2006 Sep 18;166(16):1783-4. No abstract available.

PMID:
16983059
13.

Intrahepatic CD4 T-Cell apoptosis is related to METAVIR score in patients with chronic hepatitis C virus.

Roger PM, Chaillou S, Breittmayer JP, Dahman M, St Paul MC, Chevallier P, Benzaken S, Ticchioni M, Bernard A, Dellamonica P, Tran A.

Scand J Immunol. 2005 Aug;62(2):168-75.

14.

Effect of ondansetron, a 5-HT3 receptor antagonist, on fatigue in chronic hepatitis C: a randomised, double blind, placebo controlled study.

Piche T, Vanbiervliet G, Cherikh F, Antoun Z, Huet PM, Gelsi E, Demarquay JF, Caroli-Bosc FX, Benzaken S, Rigault MC, Renou C, Rampal P, Tran A.

Gut. 2005 Aug;54(8):1169-73.

15.

Analytical variability of the Fibrotest proteins.

Rosenthal-Allieri MA, Peritore ML, Tran A, Halfon P, Benzaken S, Bernard A.

Clin Biochem. 2005 May;38(5):473-8.

PMID:
15820779
16.

Serum fibrosis markers can detect large oesophageal varices with a high accuracy.

Vanbiervliet G, Barjoan-Mariné E, Anty R, Piche T, Hastier P, Rakotoarisoa C, Benzaken S, Rampal P, Tran A.

Eur J Gastroenterol Hepatol. 2005 Mar;17(3):333-8.

PMID:
15716658
17.

[Is combined treatment with interferon alpha and ribavirin for 3 months enough in selected patients with a genotype 2 or 3 hepatitis C virus?].

Anty R, Vanbiervliet G, Benzaken S, Rampal P, Tran A.

Gastroenterol Clin Biol. 2004 Mar;28(3):304-6. French.

18.

The severity of liver fibrosis is associated with high leptin levels in chronic hepatitis C.

Piche T, Vandenbos F, Abakar-Mahamat A, Vanbiervliet G, Barjoan EM, Calle G, Giudicelli J, Ferrua B, Laffont C, Benzaken S, Tran A.

J Viral Hepat. 2004 Jan;11(1):91-6.

PMID:
14738564
19.

Diagnostic accuracy of a rapid urine-screening test (Multistix8SG) in cirrhotic patients with spontaneous bacterial peritonitis.

Vanbiervliet G, Rakotoarisoa C, Filippi J, Guérin O, Calle G, Hastier P, Mariné-Barjoan E, Schneider S, Piche T, Broussard JF, Dor JF, Benzaken S, Hébuterne X, Rampal P, Tran A.

Eur J Gastroenterol Hepatol. 2002 Nov;14(11):1257-60.

PMID:
12439122
20.

Fatigue is associated with high circulating leptin levels in chronic hepatitis C.

Piche T, Gelsi E, Schneider SM, Hébuterne X, Giudicelli J, Ferrua B, Laffont C, Benzaken S, Hastier P, Montoya ML, Longo F, Rampal P, Tran A.

Gut. 2002 Sep;51(3):434-9.

21.

High prevalence of GB virus C/hepatitis G virus infection in different risk groups of HIV-infected patients.

Clevenberg P, Durant J, Halfon P, Tran A, Manos T, Rahelinirina V, Yang G, Benzaken S, Ouzan D, Rampal P, Dellamonica P.

Clin Microbiol Infect. 1998 Jan;4(11):644-647.

22.

[Long-term lamivudine therapy for interferon-alpha- and/or adenine arabinoside monophosphate-resistant chronic hepatitis B infection. Results of a pilot study].

Tran A, Longo F, Saint-Paul MC, Doglio A, Benzaken S, Rampal P.

Gastroenterol Clin Biol. 2000 Dec;24(12):1234-5. French. No abstract available.

23.

Resting energy expenditure in chronic hepatitis C.

Piche T, Schneider SM, Tran A, Benzaken S, Rampal P, Hébuterne X.

J Hepatol. 2000 Oct;33(4):623-7.

PMID:
11059867
24.

Chondrex (YKL-40), a potential new serum fibrosis marker in patients with alcoholic liver disease.

Tran A, Benzaken S, Saint-Paul MC, Guzman-Granier E, Hastier P, Pradier C, Barjoan EM, Demuth N, Longo F, Rampal P.

Eur J Gastroenterol Hepatol. 2000 Sep;12(9):989-93.

PMID:
11007134
25.

Non invasive prediction of severe fibrosis in patients with alcoholic liver disease.

Tran A, Hastier P, Barjoan EM, Demuth N, Pradier C, Saint-Paul MC, Guzman-Granier E, Chevallier P, Tran C, Longo F, Schneider S, Piche T, Hebuterne X, Benzaken S, Rampal P.

Gastroenterol Clin Biol. 2000 Jun-Jul;24(6-7):626-30.

26.

Characterization of centromere alterations in liposarcomas.

Sirvent N, Forus A, Lescaut W, Burel F, Benzaken S, Chazal M, Bourgeon A, Vermeesch JR, Myklebost O, Turc-Carel C, Ayraud N, Coindre JM, Pedeutour F.

Genes Chromosomes Cancer. 2000 Oct;29(2):117-29.

PMID:
10959091
27.

Effects of 1-year interferon-alpha 2a treatment in patients with chronic hepatitis C and persistently normal transaminase activity.

Tran A, Longo F, Ouzan D, Bianchi D, Pradier C, Saint-Paul MC, Sattonnet C, Laffont C, Dantin S, Piche T, Benzaken S, Rampal P.

Scand J Gastroenterol. 2000 Apr;35(4):433-7.

PMID:
10831269
28.

[Prevalence of hepatitis C in patients with chronic inflammatory bowel disease in the region of Nice and evaluation of risk factors].

Longo F, Hebuterne X, Tran A, Staccini P, Hastier P, Schneider S, Benzaken S, Tirtaine C, Rampal P.

Gastroenterol Clin Biol. 2000 Jan;24(1):77-81. French.

29.

Paraneoplastic pemphigus presenting as erosive lichen planus.

Passeron T, Bahadoran P, Lacour JP, Perrin C, Gilbert D, Benzaken S, Fuzibet JG, Ortonne JP.

Br J Dermatol. 1999 Mar;140(3):552-3. No abstract available.

PMID:
10233293
30.

Lack of influence of hepatitis G virus infection on alcohol-related hepatic lesions.

Tran A, Hastier P, Longo F, Yang G, Ouzan D, Durant J, Follana R, Buckley M, Saint-Paul MC, Doglio A, Rampal P, Benzaken S.

Scand J Gastroenterol. 1998 Nov;33(11):1209-12.

PMID:
9867101
31.

Hepatitis G virus (HGV) and antibodies to a putative HGV envelope protein in alcoholic patients in southeastern France.

Tran A, Hastier P, Yang G, Longo F, Ouzan D, Durant J, Follana R, Buckley M, Saint-Paul MC, Doglio A, Rampal P, Benzaken S.

Am J Gastroenterol. 1998 Sep;93(9):1599-600. No abstract available.

PMID:
9732966
32.

Colchicine in pyoderma gangrenosum.

Rampal P, Benzaken S, Schneider S, Hebuterne X.

Lancet. 1998 Apr 11;351(9109):1134-5. No abstract available.

PMID:
9660612
33.

Phenotyping of intrahepatic and peripheral blood lymphocytes in patients with chronic hepatitis C.

Tran A, Yang G, Doglio A, Ticchioni M, Laffont C, Durant J, Bernard JL, Gugenheim J, Saint-Paul MC, Bernard A, Rampal P, Benzaken S.

Dig Dis Sci. 1997 Dec;42(12):2495-500.

PMID:
9440626
34.

Significance of serum immunoglobulin M to hepatitis C virus core in patients with chronic hepatitis C.

Tran A, Yang G, Dreyfus G, Rouquié P, Durant J, Rampal A, Rampal P, Benzaken S.

Am J Gastroenterol. 1997 Oct;92(10):1835-8.

PMID:
9382047
35.

Antibodies to GAD in chronic hepatitis C patients.

Hiéronimus S, Fredenrich A, Tran A, Benzaken S, Fénichel P.

Diabetes Care. 1997 Jun;20(6):1044. No abstract available.

PMID:
9167125
36.

Chronic hepatitis C and autoimmunity: good response to immunosuppressive treatment.

Tran A, Benzaken S, Yang G, Schneider S, Doglio A, Rampal A, Rampal P.

Dig Dis Sci. 1997 Apr;42(4):778-80. No abstract available.

PMID:
9125648
37.

[Prevalence of serum anti-hepatitis E virus antibodies in patients with human immunodeficiency virus infection].

Tran A, Broussard JF, Durant J, Broussard N, Dellamonica P, Rampal P, Benzaken S.

Gastroenterol Clin Biol. 1997;21(5):440. French. No abstract available.

38.

Effects of cyclic enteral nutrition on the immunological status of malnourished patients.

Schneider S, Hébuterne X, Benzaken S, Hastier P, Tran A, Rampal P.

Clin Nutr. 1996 Aug;15(4):189-95.

PMID:
16844033
39.

[Anti-thyroid autoantibodies in hepatitis C. Thyroid function after interferon therapy in 4 patients].

Broussard JF, Tran A, Benzaken S, Quaranta JF, Frédenrich A, Dreyfus G, Rampal P.

Presse Med. 1995 Nov 18;24(35):1645-7. French.

PMID:
8545383
40.

Anti-GOR and anti-thyroid autoantibodies in patients with chronic hepatitis C.

Tran A, Benzaken S, Braun HB, Fredenrich A, Dreyfus G, Durant J, Hiéronimus S, Quaranta JF, Ouzan D, Michel G.

Clin Immunol Immunopathol. 1995 Nov;77(2):127-30. Erratum in: Clin Immunol Immunopathol 1996 Jan;78(1):97.

PMID:
7586719
41.

High prevalence of thyroid autoantibodies in a prospective series of patients with chronic hepatitis C before interferon therapy.

Tran A, Quaranta JF, Benzaken S, Thiers V, Chau HT, Hastier P, Regnier D, Dreyfus G, Pradier C, Sadoul JL, et al.

Hepatology. 1993 Aug;18(2):253-7.

PMID:
7687977
42.

Prolongation of heart xenograft survival after liver hemoperfusion.

Amorosa L, Gugenheim J, Saint-Paul MC, Benzaken S, Mouiel J.

Transplant Proc. 1990 Aug;22(4):2002-3. No abstract available.

PMID:
2389509
43.

Vitiligo: peripheral T-cell subset imbalance as defined by monoclonal antibodies.

Soubiran P, Benzaken S, Bellet C, Lacour JP, Ortonne JP.

Br J Dermatol. 1985 Jul;113 Suppl 28:124-7. No abstract available.

PMID:
3893518
44.

HLA in families with Down's syndrome children.

Soubiran P, Benzaken S, Piereschi J, Ferrari M, Lambert JC, Ayraud N.

Tissue Antigens. 1985 Feb;25(2):103-6.

PMID:
3158098
45.

[Renal risk in vaccination].

Jacquot C, Benzaken S, Druet P.

Nouv Presse Med. 1982 Nov 6;11(44):3237-8. French. No abstract available.

PMID:
7155824

Supplemental Content

Loading ...
Support Center